Amyloidosis

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Amyloidosis is an uncommon plasma-cell dyscrasia with an incidence of eight patients per million per year. It is often difficult to recognize because of the myriad symptoms and vague nature of the clinical presentation. Symptoms include fatigue, dyspnea, edema, paresthesias, and weight loss. Clinical syndromes at presentation include nephrotic-range proteinuria with or without renal insufficiency, cardiomyopathy, hepatomegaly, symptomatic peripheral neuropathy, and autonomic failure. Recent advances have occurred in evaluation of patients by using the free light chain assay and new prognostic assessments with cardiac biomarkers. Newly developed therapeutic strategies, involving high-dose and intermediate-dose chemotherapy, have evolved in the last 3 years. This paper reviews a diagnostic pathway clinicians can use to diagnose the disorder, assess a patient's prognosis, and logically plan a therapeutic strategy.

Original languageEnglish (US)
Pages (from-to)709-727
Number of pages19
JournalBest Practice and Research: Clinical Haematology
Volume18
Issue number4 SPEC. ISS.
DOIs
StatePublished - Dec 2005

Fingerprint

Chemotherapy
Biomarkers
Amyloidosis
Assays
Fatigue of materials
Plasmas
Paraproteinemias
Hepatomegaly
Paresthesia
Peripheral Nervous System Diseases
Cardiomyopathies
Proteinuria
Dyspnea
Renal Insufficiency
Fatigue
Weight Loss
Edema
Light
Drug Therapy
Incidence

Keywords

  • Amyloid
  • Amyloidosis
  • Cardiomyopathy
  • Monoclonal gammopathy
  • Multiple myeloma
  • Nephrotic syndrome
  • Stem-cell transplantation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Amyloidosis. / Gertz, Morie; Lacy, Martha; Dispenzieri, Angela; Hayman, Suzanne R.

In: Best Practice and Research: Clinical Haematology, Vol. 18, No. 4 SPEC. ISS., 12.2005, p. 709-727.

Research output: Contribution to journalArticle

Gertz, Morie ; Lacy, Martha ; Dispenzieri, Angela ; Hayman, Suzanne R. / Amyloidosis. In: Best Practice and Research: Clinical Haematology. 2005 ; Vol. 18, No. 4 SPEC. ISS. pp. 709-727.
@article{45e24a75929a4696bbea2cbe2d4fe881,
title = "Amyloidosis",
abstract = "Amyloidosis is an uncommon plasma-cell dyscrasia with an incidence of eight patients per million per year. It is often difficult to recognize because of the myriad symptoms and vague nature of the clinical presentation. Symptoms include fatigue, dyspnea, edema, paresthesias, and weight loss. Clinical syndromes at presentation include nephrotic-range proteinuria with or without renal insufficiency, cardiomyopathy, hepatomegaly, symptomatic peripheral neuropathy, and autonomic failure. Recent advances have occurred in evaluation of patients by using the free light chain assay and new prognostic assessments with cardiac biomarkers. Newly developed therapeutic strategies, involving high-dose and intermediate-dose chemotherapy, have evolved in the last 3 years. This paper reviews a diagnostic pathway clinicians can use to diagnose the disorder, assess a patient's prognosis, and logically plan a therapeutic strategy.",
keywords = "Amyloid, Amyloidosis, Cardiomyopathy, Monoclonal gammopathy, Multiple myeloma, Nephrotic syndrome, Stem-cell transplantation",
author = "Morie Gertz and Martha Lacy and Angela Dispenzieri and Hayman, {Suzanne R.}",
year = "2005",
month = "12",
doi = "10.1016/j.beha.2005.01.030",
language = "English (US)",
volume = "18",
pages = "709--727",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "4 SPEC. ISS.",

}

TY - JOUR

T1 - Amyloidosis

AU - Gertz, Morie

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Hayman, Suzanne R.

PY - 2005/12

Y1 - 2005/12

N2 - Amyloidosis is an uncommon plasma-cell dyscrasia with an incidence of eight patients per million per year. It is often difficult to recognize because of the myriad symptoms and vague nature of the clinical presentation. Symptoms include fatigue, dyspnea, edema, paresthesias, and weight loss. Clinical syndromes at presentation include nephrotic-range proteinuria with or without renal insufficiency, cardiomyopathy, hepatomegaly, symptomatic peripheral neuropathy, and autonomic failure. Recent advances have occurred in evaluation of patients by using the free light chain assay and new prognostic assessments with cardiac biomarkers. Newly developed therapeutic strategies, involving high-dose and intermediate-dose chemotherapy, have evolved in the last 3 years. This paper reviews a diagnostic pathway clinicians can use to diagnose the disorder, assess a patient's prognosis, and logically plan a therapeutic strategy.

AB - Amyloidosis is an uncommon plasma-cell dyscrasia with an incidence of eight patients per million per year. It is often difficult to recognize because of the myriad symptoms and vague nature of the clinical presentation. Symptoms include fatigue, dyspnea, edema, paresthesias, and weight loss. Clinical syndromes at presentation include nephrotic-range proteinuria with or without renal insufficiency, cardiomyopathy, hepatomegaly, symptomatic peripheral neuropathy, and autonomic failure. Recent advances have occurred in evaluation of patients by using the free light chain assay and new prognostic assessments with cardiac biomarkers. Newly developed therapeutic strategies, involving high-dose and intermediate-dose chemotherapy, have evolved in the last 3 years. This paper reviews a diagnostic pathway clinicians can use to diagnose the disorder, assess a patient's prognosis, and logically plan a therapeutic strategy.

KW - Amyloid

KW - Amyloidosis

KW - Cardiomyopathy

KW - Monoclonal gammopathy

KW - Multiple myeloma

KW - Nephrotic syndrome

KW - Stem-cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=22144472237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144472237&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2005.01.030

DO - 10.1016/j.beha.2005.01.030

M3 - Article

C2 - 16026746

AN - SCOPUS:22144472237

VL - 18

SP - 709

EP - 727

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 4 SPEC. ISS.

ER -